Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

728
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
728
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
917
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practices and perceptions of imaging assessment in inflammatory bowel disease: a nationwide survey of physicians in Korea by the KASID Guidelines Taskforce Team.

Intestinal research·2026
Same author

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team.

Intestinal research·2026
Same author

Long-term clinical course, treatment patterns, and prognosis in pediatric-onset vs. adult-onset IBD: a multicenter retrospective cohort study in Korea.

BMC gastroenterology·2026
Same author

Ultra-Processed Foods and Inflammatory Bowel Disease: A Narrative Review of Epidemiology, Mechanisms, and Dietary Implications.

Nutrients·2025
Same author

The Effect of the Anteroposterior Position of Miniscrew Assisted Rapid Palatal Expansion on the Expansion Outcomes in Mature Patients.

Orthodontics & craniofacial research·2025
Same author

Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease.

The Korean journal of internal medicine·2025
Same journal

Macro-Aspartate Aminotransferase Elevation in a Patient with Chronic Hepatitis B.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same journal

Fatal Clinical Course of Hepatic Portal Venous Gas Associated with Thrombosed Abdominal Aortic Aneurysm.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same journal

Risk Factors for Adverse Circulatory and Respiratory Events in Patients Undergoing Esophageal Endoscopic Submucosal Dissection Under Dexmedetomidine-Based Sedation.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same journal

[Achievements and Future Directions of the National Colorectal Cancer Screening Program in Korea].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same journal

[Advanced Combination Therapy in Inflammatory Bowel Disease].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same journal

[Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K

[Golimumab Therapy in Ulcerative Colitis].

Won Moon1

  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi
|February 25, 2016
PubMed
Summary
This summary is machine-generated.

Golimumab is a new biologic therapy for ulcerative colitis, offering a safe and effective treatment option comparable to existing anti-tumor necrosis factor alpha (TNF-α) agents for moderate to severe disease.

Keywords:
AdalimumabGolimumabInfliximabTumor necrosis factor-alphaUlcerative colitis

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.1K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 25, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.1K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.8K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colon.
  • Current treatments include 5-aminosalicylic acid, steroids, thiopurines, and anti-tumor necrosis factor alpha (TNF-α) antibodies.
  • Golimumab represents a novel anti-TNF-α therapy for moderate to severe UC.

Purpose of the Study:

  • To review the efficacy and safety of golimumab in ulcerative colitis treatment.
  • To compare golimumab with established anti-TNF-α therapies like infliximab and adalimumab.

Main Methods:

  • Review of preclinical and clinical studies on golimumab in UC.
  • Analysis of golimumab's safety and efficacy profile.

Main Results:

  • Golimumab demonstrates comparable efficacy and safety to infliximab and adalimumab.
  • Preclinical and clinical data support golimumab's role in UC management.

Conclusions:

  • Golimumab is an effective and safe therapeutic option for moderate to severe ulcerative colitis.
  • This review highlights golimumab's potential in the evolving landscape of UC treatment.